Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing

Disease Markers

Volumn 30, Issue 4, 2011, Pages 151-161

  Vasiljević, Nataša ^a   Wu, Keqiang ^a   Brentnall, Adam R ^a   Kim, Dae Cheol ^a   Thorat, Mangesh A ^a   Kudahetti, Sakunthala C ^a   Mao, Xueying ^a   Xue, Liyan ^a   Yu, Yongwei ^b   Shaw, Greg L ^c   Beltran, Luis ^c   Lu, Yong Jie ^a   Berney, Daniel M ^a   Cuzick, Jack ^a   Lorincz, Attila T ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c WHIPPS CROSS UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

biomarker; BPH; DNA Methylation; Prostate cancer; pyrosequencing

Indexed keywords

APC; CD146 ANTIGEN; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GLUTATHIONE TRANSFERASE P1; HLA A ANTIGEN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN BCL 2; PROTEIN TWIST 1; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SLIT2 PROTEIN; TRANSCRIPTION FACTOR NKX2.5; TRANSCRIPTION FACTOR TWIST; UNCLASSIFIED DRUG; UVOMORULIN;

ADULT; AGED; ARTICLE; CCND 2 GENE; CHD 13 GENE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; EDNRB GENE; EGFR 5 GENE; ESR 1 GENE; GENE; GENE IDENTIFICATION; HIN 1 GENE; HUMAN; LIMIT OF QUANTITATION; MAL GENE; MALE; PDLIM 4 GENE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PTGS 2 GENE; PYROSEQUENCING; RARB GENE; SFN GENE; THRB GENE; TIG 1 GENE;

EID: 79959764747     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.3233/DMA-2011-0790     Document Type: Article

References (53)

1. D.M. Parkin, S.L. Whelan, J. Ferlay et al., Cancer Incidence in Five Continents, IARC Scientific Publications 143 (1997).
2. F.H. Schroder, J. Hugosson, M.J. Roobol et al., Screening and prostate-cancer mortality in a randomized European study, N Engl J Med 360 (2009), 1320-1328.
3. A.L. Moore, P. Dimitropoulou, A. Lane et al., Populationbased prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer, BJU Int 104 (2009), 1592-1598.
4. E. Li, C. Beard, A.C. Forster et al., DNAmethylation, genomic imprinting, and mammalian development, Cold Spring Harb Symp Quant Biol 58 (1993), 297-305. (Pubitemid 24219490)
5. T. Haaf, Methylation dynamics in the early mammalian embryo: implications of genome reprogramming defects for development, Curr Top Microbiol Immunol 310 (2006), 13-22. (Pubitemid 47400283)
6. C.P.Walsh, J.R. Chaillet and T.H. Bestor, Transcription of IAP endogenous retroviruses is constrained by cytosine methylation, Nat Genet 20 (1998), 116-117. (Pubitemid 28455441)
7. M. Esteller, P.G. Corn, S.B. Baylin et al., A gene hypermethylation profile of human cancer, Cancer Res 61 (2001), 3225-3229. (Pubitemid 32695003)
8. W.H. Lee, R.A. Morton, J.I. Epstein et al., Cytidine methylation of regulatory sequences near the pi-class glutathione Stransferase gene accompanies human prostatic carcinogenesis, Proc Natl Acad Sci U S A 91 (1994), 11733-11737. (Pubitemid 24356419)
9. B. Kwabi-Addo, W. Chung, L. Shen et al., Age-related DNA methylation changes in normal human prostate tissues, Clin Cancer Res 13 (2007), 3796-3802. (Pubitemid 47037584)
10. P.J. Bastian, J. Ellinger, A. Wellmann et al., Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci, Clin Cancer Res 11 (2005), 4097-4106. (Pubitemid 40791574)
11. R. Maruyama, S. Toyooka, K.O. Toyooka et al., Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features, Clin Cancer Res 8 (2002), 514-519. (Pubitemid 34193971)
12. S. Yegnasubramanian, J. Kowalski, M.L. Gonzalgo et al., Hypermethylation of CpG islands in primary and metastatic human prostate cancer, Cancer Res 64 (2004), 1975-1986. (Pubitemid 38339443)
13. M. Yamanaka, M.Watanabe, Y. Yamada et al., Altered methylation of multiple genes in carcinogenesis of the prostate, Int J Cancer 106 (2003), 382-387. (Pubitemid 36870401)
14. C. Jeronimo, R. Henrique, M.O. Hoque et al., A quantitative promoter methylation profile of prostate cancer, Clin Cancer Res 10 (2004), 8472-8478. (Pubitemid 40053412)
15. D.K. Vanaja, K.V. Ballman, B.W. Morlan et al., PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer, Clin Cancer Res 12 (2006), 1128-1136. (Pubitemid 43342500)
16. E. Rosenbaum, M.O. Hoque, Y. Cohen et al., Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy, Clin Cancer Res 11 (2005), 8321-8325. (Pubitemid 41746943)
17. N. Y. Cho, B. H. Kim, M. Choi et al., Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features, J Pathol 211 (2007), 269-277. (Pubitemid 46172702)
18. W. G. Nelson, A. M. De Marzo and S.Yegnasubramanian, Epigenetic alterations in human prostate cancers, Endocrinology 150 (2009), 3991-4002.
19. I. Krop, A. Player, A. Tablante et al., Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types, Mol Cancer Res 2 (2004), 489-494. (Pubitemid 39281730)
20. R. Singal, L. Ferdinand, I.M. Reis et al.,Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease, Oncol Rep 12 (2004), 631-637.
21. J. G. Herman, J. R. Graff, S. Myohanen et al., Methylationspecific PCR: a novel PCR assay for methylation status of CpG islands, Proc Natl Acad Sci U S A 93 (1996), 9821-9826. (Pubitemid 26296693)
22. C.A. Eads, K.D. Danenberg, K. Kawakami et al., MethyLight: a high-throughput assay tomeasure DNA methylation, Nucleic Acids Res 28 (2000), E32.
23. D.F. Ransohoff, Rules of evidence for cancer molecular-marker discovery and validation, Nat Rev Cancer 4 (2004), 309-314. (Pubitemid 38525286)
24. J. Cuzick, G. Fisher, M.W. Kattan et al., Long-term outcome among men with conservatively treated localised prostate cancer, Br J Cancer 95 (2006), 1186-1194. (Pubitemid 44658482)
25. J. Zhang, L. Liu, G.P. Pfeifer, Methylation of the retinoid response gene TIG1 in prostate cancer correlates with methylation of the retinoic acid receptor beta gene, Oncogene 23 (2004), 2241-2249. (Pubitemid 38482540)
26. R. Henrique, F. R. Ribeiro, D. Fonseca et al., High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients, Clin Cancer Res 13 (2007), 6122-6129. (Pubitemid 350075071)
27. R. Henrique, C. Jeronimo,M.O. Hoque et al., Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions, DNA Cell Biol 24 (2005), 264-269. (Pubitemid 40490265)
28. W. Chung, B. Kwabi-Addo, M. Ittmann et al., Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling, PLoS One 3 (2008), e2079.
29. J.W. Liu, J.K. Nagpal, C. Jeronimo et al., Hypermethylation of MCAM gene is associated with advanced tumor stage in prostate cancer, Prostate 68 (2008), 418-426. (Pubitemid 351342647)
30. K.L. Ostrow, H.L. Park, M.O. Hoque et al., Pharmacologic unmasking of epigenetically silenced genes in breast cancer, Clin Cancer Res 15 (2009), 1184-1191.
31. Y. Ling, X. Xu, J. Hao et al., Aberrant methylation of the THRB gene in tissue and plasma of breast cancer patients, Cancer Genet Cytogenet 196, 140-145.
32. A. Dallol, N.F. Da Silva, P. Viacava et al., SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers, Cancer Res 62 (2002), 5874-5880. (Pubitemid 35204748)
33. L. Mora-Garcia Mde, A. Duenas-Gonzalez, J. Hernandez- Montes et al., Up-regulation ofHLAclass-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid, J Transl Med 4 (2006), 55.
34. Q. Feng, S. E. Hawes, J. E. Stern et al., Promoter hypermethylation of tumor suppressor genes in urine from patients with cervical neoplasia, Cancer Epidemiol Biomarkers Prev 16 (2007), 1178-1184. (Pubitemid 46984956)
35. B. W. Futscher, M. M. O'Meara, C. J. Kim et al., Aberrant methylation of themaspin promoter is an early event in human breast cancer, Neoplasia 6 (2004), 380-389. (Pubitemid 38924853)
36. S. Marsh, Pyrosequencing applications, Methods Mol Biol 373 (2007), 15-24.
37. J.I. Epstein, W.C. Allsbrook, Jr., M.B. Amin et al., The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma, Am J Surg Pathol 29 (2005), 1228-1242. (Pubitemid 41232997)
38. L.C. Li, R.Dahiya, MethPrimer: designing primers formethylation PCRs, Bioinformatics 18 (2002), 1427-1431. (Pubitemid 35414532)
39. J. Tost and I.G. Gut, DNA methylation analysis by pyrosequencing, Nat Protoc 2 (2007), 2265-2275. (Pubitemid 351575045)
40. Y. Benjamini and Y. Hochberg, Controlling the false discovery rate: A practical and powerful approach to multiple testing, Journal of the Royal Statistical Society 57 (1995), 289-300.
41. J. Cuzick, A Wilcoxon-type test for trend, Stat Med 4 (1985), 87-90. (Pubitemid 15142530)
42. L. Breiman, Random Forests, Machine Learning 45 (2001), 5-32. (Pubitemid 32933532)
43. R.D.C. Team. R: A Language and Environment for Statistical Computing R Foundation for Statistical Computing Vienna, Austria, 2009.
44. D. Hessels, G. W. Verhaegh, J. A. Schalken, et al., Applicability of biomarkers in the early diagnosis of prostate cancer, Expert Rev Mol Diagn 4 (2004), 513-526. (Pubitemid 38915277)
45. R. Mehra, S.A. Tomlins, J. Yu et al., Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer, Cancer Res 68 (2008), 3584-3590.
46. D.M. Berney, A. Gopalan, S. Kudahetti et al., Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans- Atlantic Prostate Group study, Br J Cancer 100 (2009), 888-893.
47. C.S. Foster, A.R. Dodson, L. Ambroisine et al., Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement, Br J Cancer 101 (2009), 1137-1144.
48. P.J. Bastian, S. Yegnasubramanian, G.S. Palapattu et al., Molecular biomarker in prostate cancer: the role of CpG island hypermethylation, Eur Urol 46 (2004), 698-708. (Pubitemid 39488398)
49. M.H. Lee and G. Lozano, Regulation of the p53-MDM2 pathway by 14-3-3 sigma and other proteins, Semin Cancer Biol 16 (2006), 225-234. (Pubitemid 43796127)
50. S.S. Teoh, J.C.Whisstock and P.I. Bird, Maspin (SERPINB5) is an obligate intracellular serpin, J Biol Chem 285 (2010), 10862-10869.
51. C.R. Pierson, R. McGowen, D. Grignon et al., Maspin is up-regulated in premalignant prostate epithelia, Prostate 53 (2002), 255-262. (Pubitemid 35398496)
52. L.C. Li, P.R. Carroll and R. Dahiya, Epigenetic changes in prostate cancer: implication for diagnosis and treatment, J Natl Cancer Inst 97 (2005), 103-115. (Pubitemid 40277090)
53. I. Krop, M.T. Parker, N. Bloushtain-Qimron et al., HIN-1, an inhibitor of cell growth, invasion, and AKT activation, Cancer Res 65 (2005), 9659-9669. (Pubitemid 41541441)